Can an injection restore hearing? new trial tests DX243 in older adults

NCT ID NCT07637981

Recruiting now Disease control Sponsor: Dendrogenix Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests an investigational drug called DX243 in people with mild to moderate age-related hearing loss. Participants receive daily injections of DX243 or a placebo for 29 days. The study checks whether the drug is safe and whether it improves hearing, using speech-in-noise tests and questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DX243
What this could lead to: If effective, DX243 could offer a new treatment to improve hearing in older adults with mild to moderate hearing loss.
What could go wrong: This is an early-phase trial with only 24 participants, so results may not apply broadly. Safety and efficacy are still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE RELATED HEARING LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

presbycusis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE RELATED HEARING LOSS

Contacts and locations

Locations

Centre hospitalier Universitaire de Liège Sart Tilman
RECRUITING

Liège, Liège, 4000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.